Objective: The epidemiology of atrial fibrillation (AF) among Aboriginal Australians is poorly described. We compared risk factors, incidence rates and mortality outcomes for firstever hospitalised AF among Aboriginal and non-Aboriginal Western Australians 20-84 years.
What is already known about this subject?
Despite evidence of significant disparities between Aboriginal and non-Aboriginal people in the incidence and prevalence of antecedents of cardiovascular disease, there have been few publications focusing on atrial fibrillation in Aboriginal Australians or minority Indigenous populations in other industrialised countries.
What does this study add?
This first population-based comparison of antecedent risk factors and initial hospitalisation rates for AF and outcomes between Aboriginal and non-Aboriginal Australians shows that, despite AF usually being an age-related condition, their impacts are evident at much younger ages among Aboriginal than non-Aboriginal populations. One-year (but not 30-day) mortality following first admission was substantially higher among Aboriginal people.
How might this impact on clinical practice?
Clinicians should screen for cardiovascular disease and associated risk factors in early adulthood, including a high index of suspicion for early-onset AF in Aboriginal Australians.
Systems for discharge and service integration between hospital and primary care need to be enhanced to increase long-term use of medications for preventing AF-related complications, thereby improving survival.
INTRODUCTION (2.988)
Atrial fibrillation (AF), the most common serious sustained cardiac dysrhythmia, is reaching epidemic proportions globally because of its increasing incidence and prevalence, and the ageing of the population. [1] [2] [3] [4] Heart failure and stroke are common complications, with AF contributing to 15-20% of strokes and being independently associated with a 50-90% increase in mortality risk 5 and significant physical disability. 6 A recent assessment of the global burden of AF showed substantial geographical variation 3 , being higher in developed countries. While more research on AF in developing countries has been recommended, 3, 4 data regarding AF among Indigenous populations in developed countries are also sparse, despite documented high rates of predisposing factors.
7-10
Australia's Indigenous population (Aboriginal and Torres Strait Islander people, hereafter referred to as Aboriginal) have experienced significant social and health disadvantage since colonisation, manifesting in a life expectancy more than a decade shorter than other Australians. 11 Aboriginal Australians (3% of total 12 ) are geographically, linguistically, culturally and historically diverse, yet across all jurisdictions have a young age structure 12 and a heavy burden of chronic diseases like diabetes, cardiovascular diseases (CVD), chronic kidney disease (CKD) and chronic obstructive pulmonary disease (COPD). 10 Although
Aboriginal people have access to Australia's universal health insurance scheme, the agestandardised burden of CVD among Aboriginal Australians is 4·6 times greater than that of non-Aboriginal people. 10 The occurrence of many CVDs associated with AF is substantially higher in Aboriginal Australians, with rate ratios being much higher at younger ages and among women. 10 Evidence of this has been documented in recent studies of rheumatic heart disease (RHD), 13 acute myocardial infarction (AMI) 14, 15 , HF 16 and stroke 17 , yet AF in Aboriginal Australians remains poorly described in the literature. This study aimed to describe differences in the clinical profile and incidence between Aboriginal and nonAboriginal people with first-ever hospitalisations with AF in Western Australia (WA) [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . It also aimed to examine differentials in the risk of 30-day and 1-year mortality.
METHODS

Study Design
This historical cohort study accrued first-ever AF cases using administrative data. Previous event-free status and presence of comorbidities were ascertained through review of preindex-admission data. Cases were followed up for deaths within 30 days and 1-year of the first AF admission.
Data sources and definitions
Population-based de-identified linked administrative health data from 1985 to 2010 were extracted from the Hospital Morbidity Data Collection and Mortality databases, two of the primary sources within the WA Data Linkage System. 18 This comprehensive system applies probabilistic matching of records from core statutory data sets to link health data. The quality of the links has been evaluated in audits and validity studies, with the proportions of invalid (false positives) or missed links (false negatives) both estimated at 0.1% of matches. Using a fixed 15-year look-back period, the patient data were reviewed to exclude prevalent cases, retaining only first-ever hospital admissions for AF. Case numbers were summed for all study years to allow for the small numbers of Aboriginal cases.
A 10-year look-back period was used to identify comorbidity histories for first-ever AF patients based on past and current admissions. Separate variables were created for known antecedent and prognostic comorbidities, specifically 10-year histories of ischaemic heart disease (IHD), rheumatic/valvular heart disease, hypertension/hypertensive heart disease, HF, Denominators for the calculation of incidence rates comprised the sum of the population estimates for each calendar year in the study period.
Statistical analysis
Given the substantial difference in age structure between Aboriginal and non-Aboriginal populations 12 , the known early onset of CVD in Aboriginals 10, 14, 16 , and the marked variation in incidence rate ratios for other CVD over the life span [14] [15] [16] , cases were separated into two broad age groups (20-54 and 55-84 years, 54.8 years being the mean age for Aboriginal patients) for analysis of baseline characteristics, incidence rates and mortality. Baseline characteristics of Aboriginal and non-Aboriginal cases were compared using t-tests and ChiSquare tests to determine significance. Age-and sex-specific incidence rates of first hospitalisation with AF were calculated for both populations using WA census denominators.
Age-standardised rates were calculated using the classical method, with the 2006 Australian population as the standard. Aboriginal to non-Aboriginal age-specific rate ratios and their confidence intervals were calculated, with age-standardised rate ratios calculated separately for the two broad age groups. Finally, the CCI and specific disease flags were included to adjust for comorbidity history.
The proportional hazards assumption for the Cox regression models of 1 year survival was tested using Schoenfeld's test and found to be significantly violated (p=0.01) in the whole cohort analysis, but not in 30-day survivors (p=0.542). Therefore we have also provided results restricted to 30 day survivors for the 1-year survival analyses.
Interactions between Aboriginal status and a range of covariates were investigated, with age and sex interactions being significant. The full model was thus run separately for each sex and broad age group to determine whether the overall findings were applicable to substrata. A sensitivity analysis was undertaken to determine the effect of using alternative definitions of Aboriginal status.
Approval for the study was obtained from the WA Human Research Ethics Committee, the
University of WA Human Research Ethics Committee and the WA Aboriginal Health Ethics
Committee.
RESULTS
Demographic and admission profile of cases
Of the 37,097 first-ever hospital AF cases, 21,928 (59.1%) were men and 923 (2.5%) were
Aboriginal. Aboriginal patients were significantly younger than non-Aboriginal cases (47.8 % versus 11.4% <55 years, p<0.001) and more likely than non-Aboriginal cases to be women ( Table 1) . Place of residence differed significantly between the two groups, with over half of the Aboriginal cases living in very remote areas (compared with 2.7% nonAboriginals). Aboriginal patients were substantially over-represented in areas of high social disadvantage.
Non-Aboriginal patients were significantly more likely to be admitted to private hospitals and Aboriginal patients to rural hospitals (Table 1: p<0.001). Aboriginal patients were more likely to be admitted as emergency patients and almost none had private health insurance cover.
Diagnostic and comorbidity profile
Overall, AF was more likely to be the principal diagnosis in patients aged <55 (54%) than ≥55 years (29%) ( Table 1 ). Aboriginal patients were significantly more likely to have AF as a secondary diagnosis, with differences being most marked in the <55 year age group (Table   1) . Where AF was a secondary diagnosis, other CVDs were the most common principal diagnoses (41%, data not shown), with Aboriginal patients being more likely than nonAboriginal patients to have a principal diagnosis of heart failure (p=0.02) or hypertension/hypertensive heart disease in the younger age group (p=0.02) and MI in the older age group (p=0.03).
Ten-year histories of all comorbidities investigated, except stroke in the older group, were significantly more common in Aboriginal cases, with differentials higher in the younger age group, in which crude prevalence was more than four-fold for CKD, alcohol-related admissions, diabetes and rheumatic/valvular heart disease ( Table 2) . CHA 2 DS 2 -VASc scores were higher in non-rheumatic Aboriginal patients in all broad age groups with differentials greater in younger patients (p<0.001) as shown by high CHA 2 DS 2 -VASc score of 2 or more being present in 53% of Aboriginal vs 14% of non-Aboriginal patients aged <55 years (Table   3 ).
Incidence
Hospitalised AF incidence was higher in Aboriginal than non-Aboriginal patients in all age groups <65 years, with rate ratios generally reducing with age and overlapping with unity in the 65-74 year and 75-84 year age groups in men and women respectively (Figure 1 ). In the CI 561-581), respectively.
Mortality
The significant age-adjusted odds ratio (OR) of 1.75 (p<0.001) reduced steadily with incremental adjustment, with the full model finding no significant effect (OR=0.81; p=0.186)
of Aboriginal status on 30-day mortality, and diagnosis ranking and comorbidities contributing substantially to the attenuation of effect (Table 4 ). The fit of the model was excellent (C-statistic for area under the ROC curve=0.816). The fully adjusted effect was non-significant in all gender and age strata. A secondary diagnosis of AF imparted the highest adjusted risk (OR=6.53) of all covariates, particularly in the <55 year group (OR=10.58).
One-year Kaplan-Meier curves for the full cohort ( Figure 2) show a cross-over of survival, with Aboriginal patients having marginally (but statistically not significant) better early but significantly poorer later survival. For 1-year mortality in 30-day survivors, the independent association of Aboriginal status reduced with incremental adjustment, remaining significant in the full model (HR=1.58; p<0.001) despite the substantial attenuating influence of comorbidities (Table 4 , Figure 2 ). An increased Aboriginal risk of mortality was evident for men, women and the 55-84 year age group, with only the <55 year group's risk not reaching significance. The disparity remained significant in a similar analysis for the full cohort (including 30-day deaths), with a dilution of the effect size (HR=1.24; p=0.022) and only the female stratum remaining significant (Table 4 ). Different definitions of Aboriginal status produced similar findings.
DISCUSSION
This first population-based study of AF in Aboriginal Australians identified substantial differentials between Aboriginal and non-Aboriginal Western Australians in the incidence of first-ever AF hospitalisation and subsequent 1-year mortality. Aboriginal patients were younger, more likely to be women, living in rural and socio-economically disadvantaged areas and attending rural hospitals. Antecedents and other specific comorbidities were more prevalent and weighted comorbidity and CHA 2 DS 2 -VASc scores higher in Aboriginal patients across all ages, although differentials were most striking in younger patients. Agespecific rate ratios, high at young ages, reduced progressively to achieve parity by age 70 years. Thus, compared with non-Aboriginals, age-standardised rates were 3.6-fold higher in Internationally, studies of AF occurrence and outcomes in indigenous populations are rare. A linked data study using Ontario emergency department and in-hospital admissions estimated the age-adjusted incidence of AF to be 1.7 times higher in the Métis 20 years and older compared with the rest of the Ontario population. 8 A cross-sectional study of cardiometabolic disease in selected Northern Territory communities found a 3% crude prevalence of AF in its sample of 436 ( ≥18 years), with no non-Indigenous comparator. 24 Indigenous AF patients in a single-institution South Australian study had a similar age distribution and high IHD comorbidity to those in our study. 26 In a cross-sectional study linking survey and administrative male veterans data, Native Americans were found to have an age-adjusted AF prevalence of 5.4 per 100,000 compared with 5.7 and 5.2 among Whites and Pacific Islanders respectively, with Black prevalence being significantly lower. 27 Unlinked AF hospital admissions rates in Waikato, New Zealand were 1.95 and 1.45 times higher among Maori than non-Maori in 45-64 and 65 years and over age groups, respectively. 28 These studies suggest that AF incidence and prevalence rates may be higher in most indigenous compared with general populations in developed countries (except possibly USA); however differentials appear greater in Australia. Differences in epidemiological findings are likely to be influenced by study design, including the way age is controlled for in the analyses.
Among Aboriginal people hospitalised with AF, particularly at younger ages, the dysrhythmia is more likely than among non-Aboriginal people to be an emergency admission and a secondary diagnosis to other principal diseases, with CVD being the most common.
This may reflect disparities between the two ethnic groups in the detection of AF in primary health care and/or in thresholds for admission especially if AF is the principal clinical presentation. The high prevalence of other chronic diseases highlights the clinical and logistical complexity that besets hospitalisation of Aboriginal patients with AF. This requires responses being built into the patient journey at the organisational or system level. 25 The difference in AF hospitalised as a principal diagnosis also suggests there may be ascertainment bias in incidence estimates based on hospitalisations alone, resulting in underestimate of Aboriginal AF rates and therefore of the disparity.
The higher 1-year mortality but similar 30-day mortality in Aboriginal cases suggests higher underlying disease severity, poorer post-discharge management or both. Long-term underuse of anticoagulants and treatment for complications associated with AF resulting from inferior access to follow-up medical care and adherence with recommended treatments are also likely to play a role. Many of the risk factors associated with increased mortality (e.g. lack of private health insurance; presence of comorbidities) are more common in Aboriginals so that actual differentials in mortality may be higher. The comparatively higher CHA 2 DS 2 -VASc scores in non-rheumatic Aboriginal patients across all age groups reflect their higher risk of stroke and mortality, with AF likely being a marker of general vascular risk. 29 Conversely, the poorer access of Aboriginal people to ambulatory care skews hospitalized AF in Aboriginal people to higher severity, possibly inflating mortality differentials. Either way, the evidence suggests the need for more intensified out-of-hospital management of AF in
Aboriginal patients through access to specialist care and specialist support of primary care professionals, augmented by appropriate education. Access and adherence to evidence-based medications are essential for improving outcomes, yet cultural, socio-economic and logistical barriers remain. 25 Appropriate care that takes these barriers into account is central to enhancing uptake of ambulatory services. 25 The strengths of this study include being population-based; state-wide hospitalised case ascertainment with a long clearance period; a comprehensive, high quality linkage procedure 18 and an evidence-based approach to improving Indigenous identification in the system. However, the ICD coding of AF has not been validated except elsewhere 30 , and therapeutic information (including anti-coagulation) was not available in these hospital administrative data. The study is also likely to under-estimate the true community-based incidence in both populations because non-admitted patients were not captured. It is unknown whether disparities in all-of-community incidence would be greater than found here, although hospital presentation of AF is likely to be more severe in Aboriginals due to diagnostic/therapeutic delays. These limitations should be considered when interpreting these findings, with future studies addressing these caveats.
CONCLUSION
The substantial disparities in AF incidence and mortality reported in this paper have public health and clinical importance for Aboriginal Australians due to the significant morbidity and excess mortality associated with AF, including its complex interaction with other diseases. A focus on interventions for Aboriginal Australians targeting primary prevention to reduce common risk factors for AF and conditions contributing to AF (while also addressing social determinants of health) is essential. There is a concurrent need for secondary prevention including early diagnosis and treatment, and ongoing management of circulatory diseases generally and AF specifically to reduce shown disparities in outcomes. As AF is underinvestigated in the Australian Aboriginal population, further research into its epidemiology, clinical manifestations and management is required.
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Figure 2:
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Australians after first-ever Atrial Fibrillation admission (full cohort) The global chi-square test (4 df) comparing CHA 2 DS 2 -VASc score for Aboriginal and Non-Aboriginal patients was significant (p<0.001) for every age group. *Variables included in score based on administrative data: history of heart failure, hypertension, age (65-74 years=1 point; 75+ years=2 points), diabetes, cerebrovascular disease, vascular disease, sex (female=1 point) 
